PTC THERAPEUTICS, INC. 4

PTC Therapeutics Chief Technical Ops Officer Neil Gregory Almstead exercised 46,774 stock options and sold an equivalent 46,774 PTC Therapeutics (PTCT) common shares on July 6–7, 2026 under a Rule 10b5‑1 plan, ending with 60,299 shares held directly.

On July 6–7, 2026, PTC Therapeutics, Inc. Chief Technical Ops Officer Neil Gregory Almstead exercised multiple stock options at strike prices of $38.10 and $39.42 per share, acquiring 46,774 shares of common stock, and then sold a substantial portion of those shares in open‑market transactions under a pre‑arranged Rule 10b5‑1 trading plan. On July 6, 2026 he exercised 811, 18,876 and 2,474 options (total 22,161 shares) and sold 426, 385, 8,786, 10,090 and 2,474 shares (total 22,161 shares) at weighted‑average prices ranging from approximately $85.28 to $87.03 per share, largely covering the cost of the exercises and taxes. On July 7, 2026 he exercised 24,613 options and sold 3,956, 11,369 and 9,288 shares (total 24,613 shares) at weighted‑average prices from about $87.17 to $89.44 per share. After these option exercises and related sales, he beneficially owned 60,299 shares directly (plus 2,899 indirectly through his spouse), with the remaining options either partially or fully exercised as reflected in the derivative holdings table. The transactions appear to be structured, compensation‑related liquidity events rather than a net open‑market purchase or discretionary sale, and were executed pursuant to a written Rule 10b5‑1 plan adopted on November 11, 2025.

Filing Facts

CIK

1070081

Ticker

PTCT

Form

4

Source Type

fda

Accession

0001578850-26-000021

Alert Tier

6